5.23
-0.19
(-3.51%)
At close: 5:08:55 PM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 7 | 6 |
| Avg. Estimate | 204.07M | 155.18M | 572.55M | 520.64M |
| Low Estimate | 31.9M | 77M | 325M | 320.58M |
| High Estimate | 601M | 200M | 1.1B | 888.6M |
| Year Ago Sales | 93.86M | 415.48M | 682.16M | 572.55M |
| Sales Growth (year/est) | 117.44% | -62.65% | -16.07% | -9.07% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| NVV1.F | -- | -- | -- | -- |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/12/2024 |
| Reiterates | B. Riley Securities: Buy to Buy | 8/12/2024 |
| Maintains | JP Morgan: Underweight to Underweight | 8/12/2024 |
| Maintains | B. Riley Securities: Buy to Buy | 8/2/2024 |
Related Tickers
5CV.F CureVac N.V.
2.7500
+1.48%
22UA.F BioNTech SE
86.05
+1.24%
05Y.MU Vivoryon Therapeutics NV
1.7140
0.00%
HQ1.MU Oruka Therapeutics Inc. R
7.50
+2.04%
BT3.BE Lineage Cell Therapeutics Inc
0.3600
-1.10%
ARDX.MX Ardelyx, Inc.
105.50
0.00%
MVR0.BE Medivir AB
0.1372
-2.42%
P0F.F Egetis Therapeutics AB (publ)
0.2835
-2.58%
RPD.MU Royalty Pharma plc
28.29
+0.32%
2HA.F Spero Therapeutics, Inc.
0.6340
+0.16%